‘Removing the need for other partners’: Onyx invests in commercial API license

By Maggie Lynch contact

- Last updated on GMT

Image: Getty/(inoonmai)
Image: Getty/(inoonmai)

Related tags: API, Commercialization, Manufacturing, Investment, Uk, facility

Onyx invests in a commercial API license and expands its UK facility to bolster its manufacturing capabilities for niche, small-scale production.

Onyx Scientific will position itself for a commercial active pharmaceutical industry (API) license after seeing industry demand for flexible, specialist, and small-scale API manufacturing. With this investment, Onyx will also expand its UK facility​ to boost its infrastructure.

Currently, Onyx provides early phase API production services under current good manufacturing practice (GMP) regulations, but with this license it will be able to produce APIs for commercial use as its customers move their drugs to market.

Denise Bowser, commercial director at Onyx, said in a statement, “There is a growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects. We want to fill that space and remove the need for our customers to seek other partners to help them manufacture their drug substance commercially.”

Bowser added that, with its customer license in place, the company will be able to fulfill its customers’ requirements for “fast turnaround of products on a bespoke basis.”

From its initial stages of moving into the commercial manufacturing space, Onyx has worked with the Medicines and Healthcare Products Regulatory Agency and, once its license is approved, the UK facility will be able to manufacture low volumes of drug substances.

Onyx stated that it expects its API license to be approved later in 2019, with the UK facility set to produce drug substances for orphan drugs. The company said that the services provided at the plant will complement its facilities in North Carolina, US, and at its Indian sites, which offer large-scale manufacturing. 

The company will also work to implement ‘quality by design’ and ‘design of experiments’ principles into its API development and manufacturing practices.

Additionally, Onyx stated that it will expand its team of scientists and analytical and quality assurance teams with this investment.

Related news

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars